Hybrid of baculovirus and galactosylated PEI for efficient gene carrier

Department of Agricultural Biotechnology, Seoul National University, Seoul 151-921, South Korea.
Virology (Impact Factor: 3.32). 04/2009; 387(1):89-97. DOI: 10.1016/j.virol.2009.02.001
Source: PubMed


Baculovirus, containing an appropriate eukaryotic promoter, is considered an attractive approach for an efficient and safe gene delivery vehicle. However, the drawbacks of baculovirus, such as the lack of specificity and the inactivation of baculovirus by the complement system in human serum, negatively affect efficient gene delivery. Therefore, a hybrid system utilizing the positive aspects of both viral and non-viral vector systems would be useful to overcome the obstacles of either system alone. In this study, we constructed a hybrid system composed of baculovirus (B) and galactosylated polyethylenimine (GP)/DNA complexes through electrostatic interaction. The resulting GP/B hybrid had suitable physicochemical properties and low cytotoxicity for use in gene therapy. Furthermore, the GP/B significantly enhanced transduction efficiency and showed good cell-specificity compared to either viral or non-viral vector systems. These results suggest that the GP/B hybrid system can be used in gene therapy to enhance transduction efficiency and hepatocyte specificity.

Download full-text


Available from: Hu-Lin Jiang,
  • Source
    • "Moreover, polyplexes formed at an N/P ratio of 10 revealed the largest decrease in uptake when exposed to ASF-containing media suggesting that the cellular uptake is ASGP-R mediated. Kim et al (2009) described an interesting hybrid system, composed of viral and non-viral vectors, for hepatocyte targeted gene delivery via ASGP-R mediated endocytosis . These hybrid vectors were generated by combining galactosylated polyethylenimine (GP) and baculovirus (B). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ligand targeted therapy (LTT) is a powerful pharmaceutical strategy to achieve selective drug delivery to pathological cells, for both therapeutic and diagnostic purposes, with the advantage of limited side effects and toxicity. This active drug targeting approach is based on the discovery that there are receptors overexpressed on pathological cells, compared to their expression in normal tissues. The purpose of this article is to review recently published data on LTT with applications, both in the field of cancer therapy and other diseases. Moreover, data on LTT exploiting receptors overexpressed at cytoplasmatic level are also reviewed. Data were deduced from Medline (PubMed) and SciFinder and their selections were made with preference to papers where the most relevant receptors were involved. Several groups have reported improved delivery of targeted nanocarriers, as compared to nontargeted ones, to pathological cells. LTT offers several advantages, but there are also limitations in the development of this strategy. Moreover, LTT have shown encouraging results in in vitro and in animal models in vivo; hence their clinical potential awaits investigation. Recent studies highlight that the ligand density plays an important role in targeting efficacy. Furthermore, LTT applications in diseases different from cancer and those exploiting receptors overexpressed at cytoplasmatic level are growing.
    Journal of Drug Targeting 09/2011; 20(1):1-22. DOI:10.3109/1061186X.2011.611518 · 2.74 Impact Factor
  • Source
    • "Blocking the C component 5 of the complement system using antibody or cobra venom factor enhances the transduction level significantly. Recent animal studies have also revealed that simple coating of viral particles with polycationic polyethylenimine polymers can produce serum-resistant baculoviruses [41] [42]. Here, through ex vivo transduction of the cardiomyocytes, we are averting the possibility of inefficient gene delivery through in vivo viral inactivation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The potential of genetically modified cardiomyoblasts in treating damaged myocardium is well known. However, efficient delivery of these cells is of major concern during treatment. The limiting factors are the massive cell death that occurs soon after their intramyocardial transplantation into the beating heart. To address these problems, we generated recombinant baculoviruses (BacMam viruses) which efficiently transduced cardiomyoblast cells under optimized conditions. These genetically modified cells were then protected in a new polymeric microcapsule using poly-ethylene-glycol (PEG), alginate, and poly-L-lysine (PLL) polymers for efficient delivery. Results showed that microcapsules maintain cell viability and support cell proliferation for at least 30 days. The capsules exhibit strong immunoprotective potential and have high mechanical and osmotic stability with more than 70% intact capsules. The encased transduced cells showed a rapid transgene expression inside the capsule for at least 15 days. However, preclinical studies are needed to further explore its long-term functional benefits.
    BioMed Research International 01/2010; 2010:858094. DOI:10.1155/2010/858094 · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recombinant baculoviral vectors efficiently transduce many types of mammalian cells. However, their in vivo applications are hampered by the sensitivity of the virus to complement-mediated inactivation. Based on our observation that the surface charge of baculovirus is negative at neutral pH, we developed a procedure to coat baculoviral vectors with positively charged polyethylenimine 25 kDa, a commonly tested non-viral gene delivery vector, through electrostatic interaction. This coating was effective in protecting baculoviral vectors against human and rat serum-mediated inactivation in vitro, providing transduction efficiencies comparable with that generated by the control virus used under a serum-free condition. Enhanced in vivo gene expression in the liver and spleen was observed after tail vein injection of the coated viruses into mice. When injected directly into human tumor xenografts in nude mice, the coated viruses suppressed tumor development more effectively than uncoated viral vectors. These findings demonstrated the usefulness of using a simple coating method to circumvent a major obstacle to in vivo application of baculoviral vectors. The method may also serve as a flexible platform technology for improved use of the vectors, for example introducing a targeting ligand and minimizing immune responses.
    Biomaterials 08/2009; 30(29):5767-74. DOI:10.1016/j.biomaterials.2009.06.020 · 8.56 Impact Factor
Show more